Cargando…
Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were the first class of medication specifically developed for the prevention of migraine. Fremanezumab is one of four CGRP mAbs currently available and is approved by the US Food and Drug Administration (FDA) for the preventative tr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951598/ https://www.ncbi.nlm.nih.gov/pubmed/36846598 http://dx.doi.org/10.2147/NDT.S371686 |
_version_ | 1784893420870828032 |
---|---|
author | Root, Shane Ahn, Kevin Kirsch, Jack Hoskin, Justin L |
author_facet | Root, Shane Ahn, Kevin Kirsch, Jack Hoskin, Justin L |
author_sort | Root, Shane |
collection | PubMed |
description | Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were the first class of medication specifically developed for the prevention of migraine. Fremanezumab is one of four CGRP mAbs currently available and is approved by the US Food and Drug Administration (FDA) for the preventative treatment of episodic and chronic migraines. This narrative review summarizes the history of fremanezumab development, the trials that led to its approval, and the later studies published evaluating its tolerability and efficacy. Evidence of fremanezumab for clinically significant efficacy and tolerability in patients with chronic migraine is especially important when considering the high level of disability, lower quality of life scores, and higher levels of health-care utilization associated with this condition. Multiple clinical trials demonstrated superiority of fremanezumab over placebo in terms of efficacy while demonstrating good tolerability. Treatment-related adverse reactions did not differ significantly compared to placebo and dropout rates were minimal. The most commonly observed treatment-related adverse reaction was mild-to-moderate injection site reaction, described as erythema, pain, induration, or swelling at the injection site. |
format | Online Article Text |
id | pubmed-9951598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-99515982023-02-25 Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine Root, Shane Ahn, Kevin Kirsch, Jack Hoskin, Justin L Neuropsychiatr Dis Treat Review Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were the first class of medication specifically developed for the prevention of migraine. Fremanezumab is one of four CGRP mAbs currently available and is approved by the US Food and Drug Administration (FDA) for the preventative treatment of episodic and chronic migraines. This narrative review summarizes the history of fremanezumab development, the trials that led to its approval, and the later studies published evaluating its tolerability and efficacy. Evidence of fremanezumab for clinically significant efficacy and tolerability in patients with chronic migraine is especially important when considering the high level of disability, lower quality of life scores, and higher levels of health-care utilization associated with this condition. Multiple clinical trials demonstrated superiority of fremanezumab over placebo in terms of efficacy while demonstrating good tolerability. Treatment-related adverse reactions did not differ significantly compared to placebo and dropout rates were minimal. The most commonly observed treatment-related adverse reaction was mild-to-moderate injection site reaction, described as erythema, pain, induration, or swelling at the injection site. Dove 2023-02-20 /pmc/articles/PMC9951598/ /pubmed/36846598 http://dx.doi.org/10.2147/NDT.S371686 Text en © 2023 Root et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Root, Shane Ahn, Kevin Kirsch, Jack Hoskin, Justin L Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine |
title | Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine |
title_full | Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine |
title_fullStr | Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine |
title_full_unstemmed | Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine |
title_short | Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine |
title_sort | review of tolerability of fremanezumab for episodic and chronic migraine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951598/ https://www.ncbi.nlm.nih.gov/pubmed/36846598 http://dx.doi.org/10.2147/NDT.S371686 |
work_keys_str_mv | AT rootshane reviewoftolerabilityoffremanezumabforepisodicandchronicmigraine AT ahnkevin reviewoftolerabilityoffremanezumabforepisodicandchronicmigraine AT kirschjack reviewoftolerabilityoffremanezumabforepisodicandchronicmigraine AT hoskinjustinl reviewoftolerabilityoffremanezumabforepisodicandchronicmigraine |